Equifin (AMEX:II)
Historical Stock Chart
From Jun 2019 to Jun 2024
Ivivi Technologies, Inc. (AMEX:II), a leader in non-invasive,
electrotherapeutic technologies, today announced that it has retained
Jefferies & Company, Inc., the principal operating subsidiary of
Jefferies Group, Inc., as its financial advisor.
Jefferies will act as the Company’s advisor
for financings and business strategy, as well as provide assistance in
connection with the Company’s interest in
pursuing strategic partners with marketing and distribution channels for
its products.
“We look forward to working with Jefferies,
whose industry expertise will be invaluable in helping us evaluate
opportunities to maximize shareholder value," said André
DiMino, Co-CEO, Ivivi Technologies. “Jefferies’
expertise and well respected position in the capital markets should
assist management in executing its business plan.”
About Jefferies
Jefferies, a global investment bank and institutional securities firm,
has served growing and mid-sized companies and their investors for 45
years. Headquartered in New York, with more than 25 offices around the
world, Jefferies provides clients with capital markets and financial
advisory services, institutional brokerage, securities research and
asset management. The firm is a leading provider of trade execution in
equity, high yield, convertible and international securities for
institutional investors and high net worth individuals. Jefferies &
Company, Inc. is the principal operating subsidiary of Jefferies Group,
Inc. (NYSE: JEF; www.jefferies.com).
Jefferies International Limited, a UK-incorporated, wholly owned
subsidiary of Jefferies Group, Inc., was established in London in 1985
and is authorized and regulated by the Financial Services Authority
("FSA"). Jefferies International Limited is a member of the London Stock
Exchange and has Nomad accreditation on the Alternative Investment
Market (AIM), and is also a member of the Deutsche Börse
(Xetra electronic trading platform), Euronext, Oslo Bors and Dubai
International Financial Exchange (DIFX). Jefferies (Japan) Limited is a
member of the Tokyo Stock Exchange and Jasdaq Securities Exchange.
About Ivivi Technologies, Inc.
Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology
company focusing on designing, developing and commercializing its
proprietary electrotherapeutic technology platform. Ivivi’s
research and development activities are focused specifically on pulsed
electromagnetic field, or PEMF, technology, which, by creating a
therapeutic electrical current in injured soft tissue, stimulates
biochemical and physiological healing processes to help repair the
injured tissue and reduce related pain and inflammation. The Company’s
Electroceuticals™ have been used in
non-invasive treatments for a wide array of conditions, including
chronic wounds, pain and edema following plastic and reconstructive
surgery and chronic inflammatory disorders.
Forward-Looking Statements
This release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995, including the statements related to the preliminary data
discussed above. Forward-looking statements reflect management's current
knowledge, assumptions, judgment and expectations regarding future
performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give no
assurance that such expectations will prove to be correct and you should
be aware that actual results could differ materially from those
contained in the forward-looking statements. Forward-looking statements
are subject to a number of risks and uncertainties, including, but not
limited to, the Company’s limited operating
history, history of significant and continued operating losses and
substantial accumulated earnings deficit, difficulties with its
financial accounting controls, the failure of the market for the Company’s
products to continue to develop, the inability for customers to receive
third party reimbursement, the inability to obtain additional capital,
the inability to protect the Company’s
intellectual property, the loss of any executive officers or key
personnel or consultants, competition, changes in the regulatory
landscape or the imposition of regulations that affect the Company’s
products and other risks detailed from time to time in the Company’s
filings with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-KSB for
the fiscal year ended March 31, 2007. The Company assumes no obligation
to update the information contained in this press release.